The Matrix Immune Modulator™ (MIM) has recently been developed and is patent-pending as an adjuvant for increasing the efficacy of vaccines. Adjuvants comes from the Latin word adjuvare meaning "to help". Adjuvants are used to enhance an immune response when used in combination with vaccines. Since the 1940s aluminum hydroxide "Alum" has been the only stand-alone adjuvant approved by the FDA for use in human vaccines. Since then scientist have searched for better and safer adjuvants, analyzing hundreds of potential candidates. Our MIM technology answers the questions and concerns with current adjuvants.
Bioscience Vaccines has a patent portfolio of (10)
domestic and (9) international filings. Our intellectual property is protected
in the fields of use for tissue vaccines and vaccine adjuvants targeted in human and veterinary applications for the prevention and
treatment of infectious diseases and cancer. Bioscience
Vaccines’ intellectual property is owned by the University of Notre Dame and
licensed to Cook Biotech, Inc. Bioscience Vaccines has negotiated an exclusive
worldwide sub-license agreement with Cook Biotech, Inc. for all research,
development, manufacturing, marketing, and distribution rights for the use of
the MIM technology.
Bioscience Vaccines' novel MIM technology is an extracellular matrix (ECM) that surrounds cells in tissues in the body. MIM technology is derived from an abundant, naturally occurring biomaterial already FDA approved for over 100 different products for medical devices and has been used in ~2 million patients worldwide over the past 10 years. MIM's composition is porcine derived, collagen Type I, III, IV, and VI, elastin, fibronectin, laminin, glycosaminoglycans (GAGs), growth factors, and matricellular proteins. The MIM technology is in a lyophilized formulation and can be combined with current or developing vaccines in an injectable form. MIM may be added to vaccines late in vaccine manufacturing process and doesn't change/lengthen the vaccine development process. MIM is stored at room temperature (shelf life of ~18 months) and has shown to increase antibody production with no adverse effects at the injection site.
The current data indicates that the MIM technology can potentiate the immune response to various antigens, via mechanism of action particular to each antigen. In addition, the MIM technology is safe, with no adverse events seen in all models, these results are as expected from the use of the base technology in humans.
MIM enhances the efficacy of vaccines for infectious disease.In a preclinical model of tetanus, MIM improved the immune response 10 to 15-fold over alum, the only FDA approved stand alone adjuvant currently on the market. MIM is currently available in 3 different formulations (MIM90, MIM150, and MIM250) and is used as a combination product with vaccines in an injectable form.
Bioscience Vaccines' novel MIM technology enhances the efficacy of vaccines by stimulating the body's own protective (immune) response and potentially decreasing the amount of vaccine required per dose. As the vaccine market approaches $34 billion by 2012, adjuvants will serve as an important factor in the development of new and improved vaccines. Bioscience Vaccines' MIM technology is positioned to meet those needs.
The Matrix Immune Modulator™ (MIM) has recently been developed and is patent-pending as an adjuvant for increasing the efficacy of vaccines. Adjuvants comes from the Latin word adjuvare meaning "to help". Adjuvants are used to enhance an immune response when used in combination with vaccines. Since the 1940s aluminum hydroxide "Alum" has been the only stand-alone adjuvant approved by the FDA for use in human vaccines. Since then scientist have searched for better and safer adjuvants, analyzing hundreds of potential candidates. Our MIM technology answers the questions and concerns with current adjuvants. 
The current data indicates that the MIM technology can potentiate the immune response to various antigens, via mechanism of action particular to each antigen. In addition, the MIM technology is safe, with no adverse events seen in all models, these results are as expected from the use of the base technology in humans.
